Summary

Eligibility
for people ages 2-11 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
estimated completion
Principal Investigator
Philip Rosenthal

Description

Summary

The primary objective of this study is to evaluate the antiviral efficacy of tenofovir disoproxil fumarate (tenofovir DF; TDF) versus placebo in pediatric population (aged 2 to < 12 years at the time of enrollment) with chronic hepatitis B (CHB) infection.

Official Title

A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients With Chronic Hepatitis B Infection

Keywords

Chronic Hepatitis B Infection Hepatitis Hepatitis B HBV Infection Communicable Diseases Hepatitis A Hepatitis B, Chronic Hepatitis, Chronic Tenofovir Tenofovir DF

Eligibility

You can join if…

Open to people ages 2-11

  • Male or Female, 2 to < 12 years of age
  • Weight ≥ 10 kg
  • Chronic HBV infection ≥ 6 months
  • HBeAg-positive or HBeAg-negative
  • HBV Viral Load ≥ 100,000 copies/mL
  • Alanine aminotransferase (ALT) ≥ 1.5 x the upper limit of the normal range (ULN) at screening
  • Creatinine Clearance ≥ 80 mL/min/1.73m2

  • Absolute neutrophil count (ANC) ≥ 1,500/mm3, hemoglobin ≥ 10 g/dL

  • Negative pregnancy test at screening
  • No prior tenofovir DF therapy (participants may have received prior interferon-alfa and/or other oral anti-HBV nucleoside/nucleotide therapy; participants must have discontinued interferon-alfa therapy ≥ 6 months prior to screening; participants experienced on other anti-HBV nucleoside/nucleotide therapy must have discontinued therapy ≥ 16 weeks prior to screening to avoid flare if randomized to the placebo arm)

You CAN'T join if...

  • Pregnant or lactating
  • Decompensated liver disease
  • Received interferon therapy within 6 months of screening
  • Received anti-HBV nucleoside/nucleotide therapy within 16 weeks of screening
  • Alpha-fetoprotein levels > 50 ng/mL
  • Evidence of hepatocellular carcinoma (HCC)
  • Co-infection with HIV, acute hepatitis A virus (HAV), hepatitis C virus (HCV), or hepatitis D virus (HDV)
  • Chronic liver disease not due to HBV
  • History of significant renal, cardiovascular, pulmonary, neurological or bone disease
  • Long term non-steroidal, anti-inflammatory drug therapy

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Locations

  • University of California, San Francisco
    San Francisco California 94143 United States
  • Phoenix Children's Hospital
    Phoenix Arizona 85016 United States

Lead Scientist at UCSF

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Gilead Sciences
ID
NCT01651403
Phase
Phase 3
Study Type
Interventional
Last Updated